Delivery Order SPE2DB22D3019-SPE2DB25FK3NC
- Not listed
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order valued at $3,417.91 to AmerisourceBergen Drug Corp for the supply of LINZESS 290mg capsules (30-count) on September 16, 2025. The award is non-competitive and utilizes firm fixed pricing under a delivery order contract type, with performance scheduled for completion by October 10, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania, where the company...
- The Defense Logistics Agency awarded a $3,612.68 delivery order to AmerisourceBergen Drug Corp for LINZESS 290 microgram capsules (30-count units) on July 22, 2025, with an ultimate completion date of July 23, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. LINZESS is a prescription medication used to treat chronic idiopathic constipation and...
- The Defense Logistics Agency awarded a $1,678.18 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 microgram capsules (30-count units) on August 12, 2025, with completion targeted for August 13, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and is being performed at the awardee's facility in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract with DLA Troop...
- The Defense Logistics Agency awarded a $6,580.09 firm fixed price delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count units) with an ultimate completion date of September 9, 2025. This non-set-aside competitive award was issued to AmerisourceBergen's Corporate Office, headquartered in Conshohocken, Pennsylvania, which serves as a critical pharmaceutical distributor for federal medical procurement. The delivery order represents a single transaction under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count units) with a ceiling value of $1,562.53. This non-set-aside, competitively awarded contract represents a firm fixed-price delivery order with an ultimate completion date of August 26, 2025. The award was issued on August 25, 2025, with performance to be fulfilled at AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,466.94 to AmerisourceBergen Drug Corp for LINZESS 72 MCG capsules (30-count unit) on July 14, 2025, with an ultimate completion date of July 15, 2025. This firm fixed price delivery order was competitively awarded with no set-aside designation and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. LINZESS is a prescription medication used to treat irritable bowel syndrome with...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Linzess 72 microgram capsules (30-count unit of use packaging) with a ceiling value of $1,155.69. This firm fixed-price delivery order, which is expected to be completed by August 15, 2025, represents a non-competitive set-aside award and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order falls under...
- The Defense Logistics Agency awarded a delivery order valued at $1,392.69 to AmerisourceBergen Drug Corp on August 8, 2025, for the supply of Linzess 290 microgram capsules (30-count unit dose). This is a firm fixed price, competitive delivery order with no set-aside designation and an ultimate completion date of August 11, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Linzess 290 micrograms capsules (30-count units) valued at $3,746.36 on September 29, 2025, with completion targeted for September 30, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger pharmaceutical supply vehicle with DLA. The product will be delivered to the company's corporate office location in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Linzess 145 mcg capsules (30-count units) with a ceiling value of $4,586.15. This is a firm fixed-price delivery order with no set-aside designation, issued under competitive procurement procedures. The order is due for completion by September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery...
- SPE2DB22D3019Indefinite Delivery Contract
- SPE2DB22D3019-SPE2DB25FK3NCDelivery Order
The Defense Logistics Agency awarded a $4,291.87 delivery order to AmerisourceBergen Drug Corp for LINZESS 145 MCG capsules (30-count unit of use packaging) on April 24, 2025, with completion scheduled for April 25, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order will be fulfilled from AmerisourceBergen's operations in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters and serves as a major pharmaceutical distributor for federal medical procurement. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999 ceiling value through December 2026. This comprehensive pharmaceutical prime vendor contract enables AmerisourceBergen to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military and veteran healthcare systems globally, including the Defense Health Agency and U.S. Coast Guard. The current order for LINZESS, a medication used to treat irritable bowel syndrome and chronic idiopathic constipation, represents a routine fulfillment of the company's role as a critical vendor within the DLA's medical supply chain.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.3k | 4/24/25 |